Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | ESR1 | P03372 | 3/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 8/20 | 0.51 |
| ▸ | RAB9A | P51151 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417126 | 0.90 | ESR1 (0.51) | HDAC6ESR1ESR2NPC1RAB9A | |
| SCHEMBL6518045 | 0.89 | ESR1 (0.52) | HDAC6ESR1ESR2NPC1RAB9A | |
| SCHEMBL5418241 | 0.84 | APP (0.49) | HDAC6ESR1ESR2NPC1RAB9A | |
| SCHEMBL5421354 | 0.84 | APP (0.49) | HDAC6ESR1ESR2NPC1RAB9A | |
| SCHEMBL4463663 | 0.83 | ESR1 (0.54) | HDAC6ESR1ESR2NPC1RAB9A | |
| SCHEMBL4473765 | 0.82 | ESR1 (0.50) | HDAC6ESR1ESR2NPC1RAB9A | |
| SCHEMBL4478313 | 0.81 | ESR1 (0.59) | HDAC6ESR1ESR2NPC1RAB9A | |
| SCHEMBL4470101 | 0.80 | ESR2 (0.58) | HDAC6ESR1ESR2NPC1RAB9A | |
| SCHEMBL4473521 | 0.80 | ESR1 (0.58) | ESR1ESR2NPC1RAB9AMAPT | |
| SCHEMBL4468622 | 0.80 | ESR1 (0.58) | ESR1ESR2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531564-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1982713-A2 | Substituted benzoxazoles and analogues as estrogenic agents | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2007-07-19 | — | — | US | disclosed |
| EP-1781628-A2 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | Wyeth a Corporation of the State of Delaware (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7148247-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-12-12 | — | — | US | disclosed |
| US-7129258-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | BARLAAM BERNARD | 2006-05-25 | — | — | US | disclosed |
| US-7045539-B2 | Therapeutic benzoxazole compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-20060046968-A1 | Prodrug substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-03-02 | — | — | US | disclosed |
| US-20050239851-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-04-14 | — | — | US | disclosed |
| US-6794403-B2 | FOR TREATING OR INHIBITING INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE PROCTITIS OR COLITIS PROSTATIC HYPERTROPHY, UTERINE LEIOMYOMAS, BREAST CANCER, ENDOMETRIAL CANCER, CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE | WYETH | 2004-09-21 | — | — | US | disclosed |
| EP-1451165-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040102435-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | WYETH | 2003-10-23 | — | — | US | disclosed |
| EP-1345914-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003050095-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2002051821-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | ESR1, CYP19A1, ESR2 | HDAC6 1696/4885ESR1 1/4885ESR2 3/4885 |
| US-20050239851-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | HDAC6 1892/4885ESR1 1/4885ESR2 2/4885 |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | HDAC6 1892/4885ESR1 1/4885ESR2 2/4885 |
| US-20040102435-A1 | Therapeutic compounds | ESRRA, ESRRG, ESR2 | HDAC6 2988/4885ESR1 6/4885ESR2 3/4885 |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | HDAC6 1770/4885ESR1 1/4885ESR2 2/4885 |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | HDAC6 1892/4885ESR1 1/4885ESR2 2/4885 |
| US-20070208066-A1 | ER-beta-selective ligands | ESR2, ESRRG, ESRRA | HDAC6 3698/4885ESR1 5/4885ESR2 1/4885 |
| US-20060046968-A1 | Prodrug substituted benzoxazoles as estrogenic agents | ESR1, CYP19A1, ESR2 | HDAC6 1696/4885ESR1 1/4885ESR2 3/4885 |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | ESR1, ESR2, ESRRG | HDAC6 2185/4885ESR1 1/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.